Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery — A mono-institutional prospective study

• Global health status/general QoL and physical and role functioning show a significant, but transient decrease during definitive radio(chemo)therapy.
• During treatment, substantial symptoms of diarrhea, appetite loss and nausea, urinary frequency and fatigue syndrome are reported.
• Three months after the end of treatment, several functional aspects of QoL remain considerably impaired.

ObjectiveTo evaluate health-related quality of life (HR-QoL) and patient reported symptoms (PRS) before, during and early after treatment with external-beam radiotherapy (EBRT), chemotherapy and image-guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer.MethodsIn fifty consecutive patients, HR-QoL and PRS were prospectively assessed with the EORTC-QLQ-C30 + CX24 questionnaire prior to and during treatment, one week after IGABT and three months thereafter. HR-QoL was compared to an age-matched, female normative reference population. Prevalence rates of individual PRS are presented and defined as “substantial”, if reported as “quite a bit” or “very much”.ResultsGlobal health status and physical and role functioning show a highly significant decline during treatment (p ≤ 0.001), before returning to near the baseline levels three months after end of treatment. Compared to the reference population, the global health status and emotional and role functioning remain impaired. The most frequently reported substantial PRS during active treatment are: fatigue (78%), diarrhea (68%), urinary frequency (60%) and nausea (54%); these recover to some degree three months after end of treatment. However, fatigue remains increased (50%) and an onset of hot flashes (44%), sexual worries (38%) and limb edema (22%) is observed.ConclusionsSeveral impairments in HR-QoL and PRS were found during definitive radio(chemo)therapy with IGABT, with different patterns of progress over time and signs of recovery three months thereafter, although some aspects of functional HR-QoL remain impaired. These findings support a comprehensive patients' counseling on what to expect and how to organize professional, social and family life and plan additional support during this period.